Tranexamic Acid Therapy For The Treatment of Subdural Hematomas

This Phase II randomized, placebo-controlled, double-blinded trial is the first step in our endeavor to improve the clinical outcomes of patients with chronic subdural hematomas (cSDH). Patients who are deemed to not need surgery for their cSDH will be randomly assigned to either the treatment group or the placebo group. Both groups will take a 650mg tablet once daily for 21 weeks and follow the standard of care monitoring for cSDH which is neurological testing and imaging at 6 weeks, 12 weeks, and 21 weeks. With this study, we hope to establish the safety and efficacy of using TXA PO to resolve cSDH without the need for surgical intervention.

NCT Number	NCT06718751
Lead Sponsor	Baylor College of Medicine
Conditions	Chronic Subdural Hematoma
Enrollment	240 participants
Start Date	2025-10
Primary Completion	2029-10 (estimated)
Study Completion	2030-10 (estimated)
Updated on ClinicalTrials.gov	2025-05-14